We are live on !
Find out more
Decheng Capital Management III (Cayman) Portfolio holdings
AUM
$300M
Turnover
40.63%
1-Year Est. Return
15.74%
This Fund
S&P 500
This Quarter Est. Return
-10.5%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$300M
AUM Growth
-$19.2M
(-6%)
Cap. Flow
+$40.1M
Cap. Flow % of AUM
Cap. Flow %
13.37%
Top 10 Holdings %
Top 10 Hldgs %
79.17%
Holding
32
New
7
Increased
1
Reduced
2
Closed
6
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpine Immune Sciences Inc
ALPN
|
+$82.6M |
| 2 |
Roivant Sciences
ROIV
|
+$16.5M |
| 3 |
Lantheus
LNTH
|
+$10.4M |
| 4 |
Aura Biosciences
AURA
|
+$9.36M |
| 5 |
Immunogen Inc
IMGN
|
+$6.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALP.PRN
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
|
+$69M |
| 2 |
APGN
Apexigen, Inc. Common Stock
APGN
|
+$814K |
| 3 |
Adicet Bio
ACET
|
+$674K |
| 4 |
ACELYRIN
SLRN
|
+$130K |
| 5 |
NeuBase Therapeutics, Inc. Common Stock
NBSE
|
+$92.5K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Alpine Immune Sciences Inc
ALPN
| $76.8M | 25.63% |
+6,708,288
| New | +$82.6M |
2023 Q3
0 quarters
|
|
2
Zentalis Pharmaceuticals
ZNTL
$167M
| $42.1M | 14.06% |
2,099,583
| – | – |
2022 Q2
5 quarters
|
|
|
3
Aura Biosciences
AURA
$740M
| $18.2M | 6.09% |
1,163,123
+869,790
| +297% | +$9.36M |
2022 Q1
6 quarters
|
|
|
4
Roivant Sciences
ROIV
$28.6B
| $17M | 5.69% |
+1,459,700
| New | +$16.5M |
2023 Q3
0 quarters
|
|
|
5
DELISTED
ACELYRIN
SLRN
| $15.7M | 5.26% |
1,548,317
-6,100
| -0.4% | -$130K |
2023 Q2
1 quarter
|
|
6
Arcus Biosciences
RCUS
$2.51B
| $15.6M | 5.21% |
869,790
| – | – |
2022 Q1
6 quarters
|
|
7
10x Genomics
TXG
$7.65B
| $14.8M | 4.95% |
359,554
| – | – |
2022 Q1
6 quarters
|
|
8
argenx
ARGX
$60.4B
| $13.5M | 4.5% |
27,429
| – | – |
2022 Q3
4 quarters
|
|
9
Pacific Biosciences
PACB
$612M
| $12.2M | 4.08% |
1,463,872
| – | – |
2022 Q1
6 quarters
|
|
10
Illumina
ILMN
$31.3B
| $11.1M | 3.7% |
83,123
| – | – |
2022 Q1
6 quarters
|
|
|
11
Lantheus
LNTH
$6.64B
| $9.9M | 3.3% |
+142,196
| New | +$10.4M |
2023 Q3
0 quarters
|
|
|
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $9.13M | 3.05% |
78,900
| – | – |
2022 Q2
5 quarters
|
|
13
Phathom Pharmaceuticals
PHAT
$493M
| $8.81M | 2.94% |
850,000
| – | – |
2023 Q2
1 quarter
|
|
|
14
DELISTED
Immunogen Inc
IMGN
| $6.6M | 2.2% |
+415,880
| New | +$6.92M |
2023 Q3
0 quarters
|
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.88M | 1.63% |
23,014
| – | – |
2022 Q3
4 quarters
|
|
16
DELISTED
Cue Health Inc. Common Stock
HLTH
| $3.97M | 1.32% |
8,980,909
| – | – |
2022 Q1
6 quarters
|
|
17
BeyondSpring
BYSI
$24.7M
| $3.97M | 1.32% |
+4,958,143
| New | +$4.85M |
2023 Q3
0 quarters
|
|
18
DELISTED
Terns Pharmaceuticals
TERN
| $3.59M | 1.2% |
714,285
| – | – |
2022 Q1
6 quarters
|
|
19
Equillium
EQ
$101M
| $3.29M | 1.1% |
4,447,308
| – | – |
2022 Q1
6 quarters
|
|
20
Whitehawk Therapeutics
WHWK
$181M
| $2.55M | 0.85% |
526,329
| – | – |
2022 Q1
6 quarters
|
|
21
AtriCure
ATRC
$2.89B
| $2.03M | 0.68% |
+46,259
| New | +$2.26M |
2023 Q3
0 quarters
|
|
22
SCYNEXIS
SCYX
$31.9M
| $1.27M | 0.42% |
69,444
| – | – |
2022 Q1
6 quarters
|
|
23
DELISTED
Mersana Therapeutics
MRSN
| $1.15M | 0.38% |
36,171
| – | – |
2022 Q1
6 quarters
|
|
24
Pyxis Oncology
PYXS
$189M
| $650K | 0.22% |
+326,810
| New | +$757K |
2023 Q3
0 quarters
|
|
25
GeneDx Holdings
WGS
$1.57B
| $377K | 0.13% |
103,604
| – | – |
2022 Q1
6 quarters
|
|
Similar funds
IBT
3LCM
TFA
Decheng Capital Management III (Cayman)'s Q3 2023 Portfolio in Review
As of Q3 2023, Decheng Capital Management III (Cayman) held 32 positions worth $300M, down 6% from $319M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Decheng Capital Management III (Cayman) deployed $40.1M of net new capital in Q3 2023, opening 7 new positions and adding to 1 existing holding. Its largest new stake was Alpine Immune Sciences Inc: 6,708,288 shares worth $76.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 71% a quarter earlier.
On the sell side, the largest reduction was Adicet Bio, an estimated $674K trimmed.
- Decheng Capital Management III (Cayman)'s largest Q3 2023 buy was Alpine Immune Sciences Inc: 6,708,288 shares worth $76.8M.
- Decheng Capital Management III (Cayman) added most to Aura Biosciences in Q3 2023, an estimated $9.36M increase.
- Decheng Capital Management III (Cayman)'s biggest Q3 2023 reduction was Adicet Bio, cutting an estimated $674K.
- Decheng Capital Management III (Cayman) fully exited Alabama Power Co 5.20% CL-A PRF in Q3 2023, selling an estimated $69M.
- Decheng Capital Management III (Cayman)'s ten largest holdings make up 79% of its $300M portfolio in Q3 2023.
- Decheng Capital Management III (Cayman) opened 7 new positions and closed 6 in Q3 2023.
- Decheng Capital Management III (Cayman)'s portfolio value fell 6% quarter-over-quarter to $300M.
Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.